Under terms of the agreement, TAP will develop an automatedsystem capable of manipulating up to four Corning HYPERStack-120 Cell CultureVessels simultaneously, providing better control and more consistent results tolarge bioprocess customers who require high-throughput manufacturing.
"Biotherapeutic manufacturers are faced with developing moreproduct of better, first-time quality at less total manufactured cost," saidKen Ludwig, business manager, bioprocess and cell therapy at Corning LifeSciences. "To meet and exceed the needs of these customers, we seek ways todeliver innovative technologies to the market that improve results, increaseefficiencies and lower costs. Our collaboration with TAP is another proof pointof that commitment and to our focus on both automation and bioprocess."
This latest project follows a number of successfulcollaborations between the two companies. These include implementing Corningcryogenic vials on TAP's Fill It automated dispensing system, and HYPERFlaskcell culture vessels on TAP's CompacT SelecT automated cell culture system.
"TAP is excited to be working on another custom project withCorning Life Sciences," said Dave Thomas, product manager, Integrated CellCulture Systems, TAP Biosystems. "There is a strong need for automated tools toimprove production efficiency and we believe that the combination of Corningand TAP expertise will provide a significant step forward in this area."
The HYPERStack cell culture vessel features a unique,multi-layered design based on Corning's gas-permeable film technology anddelivers more cells in the same volumetric footprint compared to currentstacked-plate products. The increased surface area enables researchers toproduce more cells from the same cell population and reduce variability, aswell as use fewer vessels, which saves space and labor.
Corning's cell culture vessels for bioprocessing supportsuspension and attachment culture in various capacities and provide solutionsfrom cell line development, to seed train, to manufacturing.
